Pharmacokinetic study of VM26 given as a prolonged IV infusion to ovarian cancer patients

Cancer Chemother Pharmacol. 1984;13(3):211-4. doi: 10.1007/BF00269031.


Plasma levels of VM26 were assayed by HPLC in six ovarian cancer patients with normal renal and liver function who received the drugs as an initial 1-h IV infusion of 80 mg/m2 followed by a 24-h IV infusion of 120 mg/m2. These doses and infusion rates were chosen on the basis of mean VM26 clearance values found in a previous study, with the aim of reaching plasma steady-state levels of approximately 6 micrograms/ml in a short time. Plasma steady-state levels of 4-10 micrograms/ml, close to those predicted theoretically, were in fact attained at 4-9 h during the second, slower infusion. Mean half-lives and clearance values were 8.6 +/- 1.1 h and 0.78 +/- 0.08 l/h/m2. Six percent of the VM26 dose was recovered as unchanged drug in the urines collected up to 24 h after the end of infusion. The glucuronide of VM26 aglycone (4'-demethylepipodophyllotoxin) was identified in the urine of all patients, in amounts corresponding to about 8% of the drug dose.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Drug Administration Schedule
  • Female
  • Injections, Intravenous
  • Kinetics
  • Metabolic Clearance Rate
  • Ovarian Neoplasms / drug therapy*
  • Podophyllotoxin / analogs & derivatives*
  • Teniposide / administration & dosage*
  • Teniposide / metabolism
  • Teniposide / urine


  • Teniposide
  • Podophyllotoxin